195194-80-0

Basic information

• Product Name: 2-Piperidinone, N-[4-bromo-n-butyl]-
• Synonyms: 2-Piperidinone, N-[4-bromo-n-butyl]-
• CAS NO: 195194-80-0
• Molecular Formula: C₉H₁₆BrNO
• Molecular Weight: 234.13
• Mol File: 195194-80-0.mol

Chemical Properties

• Boiling Point: 341.1±25.0 °C(Predicted)
• Appearance: /
• Density: 1.316±0.06 g/cm3(Predicted)
• PKA: -0.47±0.20(Predicted)
• CAS DataBase Reference: 2-Piperidinone, N-[4-bromo-n-butyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Piperidinone, N-[4-bromo-n-butyl]-(195194-80-0)
• EPA Substance Registry System: 2-Piperidinone, N-[4-bromo-n-butyl]-(195194-80-0)

Safety Data

• Hazardous Substances Data: 195194-80-0(Hazardous Substances Data)

Upstream product

• 675-20-7 piperidin-2-one 
• 110-52-1 1,4-dibromo-butane 

Relevant articles and documents

Iridium-catalyzed reductive nitro-mannich cyclization

A new chemoselective reductive nitro-Mannich cyclization reaction sequence of nitroalkyl-tethered lactams has been developed. Relying on the rapid and chemoselective iridium(I)-catalyzed reduction of lactams to the corresponding enamine, subsequent nitro-

Conformational flexibility of serotonin1A receptor ligands from crystallographic data. Updated model of the receptor pharmacophore.

Preparation and affinity to 5-HT1A and 5-HT2A receptors of new buspirone analogues 7-17 are reported. The compounds possess high to low affinity to 5-HT1A and moderate to low to 5-HT2A receptors. The crystal structures have been determined for compounds 11, 12, 13, and 14. For low affinity ligand (15) of 5-HT1A receptor conformational analysis was performed and compared with similar analyses performed for know high (buspirone 1) and very high (WY-48,723 2) affinity ligands of the receptor. Structure-activity relationship is discussed for the affinity to 5-HT1A receptor. A three-point pharmacophore explaining interactions of buspirone-like molecules with the receptor binding site is proposed.

Iridium-Catalyzed Aza-Spirocyclization of Indole-Tethered Amides: An Interrupted Pictet-Spengler Reaction

A mild, reductive spirocyclization of indole-linked amides and lactams for the efficient and selective synthesis of aza-spirocyclic indoline products is described. The catalytic reductive activation of tertiary amides or lactams by Vaska's complex with tetramethyldisiloxane as the terminal reductant allowed iminium ion formation, before a diastereoselective 5-endo-trig spirocyclization of the tethered indole moiety was triggered. Terminal reduction affords the aza-spiroindoline products in an overall highly chemoselective and diastereoselective one-pot process.

Computer-assisted design, synthesis, binding and cytotoxicity assessments of new 1-(4-(aryl(methyl)amino)butyl)-heterocyclic sigma 1 ligands

In this work we applied a blend of computational and synthetic techniques with the aim to design, synthesize, and characterize new σ1 receptor (σ1R) ligands. Starting from the structure of previously reported, high-affinity benzoxazolone-based σ1 ligands, the three-dimensional homology model of the σ1R was exploited for retrieving the molecular determinants to fulfill the optimal pharmacophore requirements. Accordingly, the benzoxazolone moiety was replaced by other heterocyclic scaffolds, the relevant conformational space in the σ1R binding cavity was explored, and the effect on σ1R binding affinity was ultimately assessed. Next, the compounds designed in silico were synthesized, and their affinity and selectivity toward σ1and σ2receptors were tested. Finally, a representative series of best σ1R binders were assayed for cytotoxic activity on the SH-SY5Y human neuroblastoma cell line. Specifically, the new 4-phenyloxazolidin-2-one derivatives 2b (i.e., (R)-2b and (S)-2b) emerged as potential leads for further development as σ1R agents, as they were found endowed with the highest σ1R affinity (Kiσ1 values in the range 0.95–9.3?nM), and showed minimal cytotoxic levels exhibited in the selected, cell-based test, in line with a σ1R agonist behavior.

5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists

This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof wherein A is independently halo; Y1 is —(CH2)m—, C(O) or S(O); Y2 is N or CH; R1 and R2 are independently C1-4 alkyl; R3 is selected from the following: (a) optionally substituted —(CH2)p—C3-7 cycloalkyl; (b) optionally substituted —C5-7 alkyl; and (c) substituted —C1-4 alkyl; and (d) optionally substituted C7- bicycloalkyl; R4 is optionally substituted thiazolyl, imidazolyl or oxazolyl; X is S, —NH, —N—C1-4 alkyl or O; R5 is hydrogen or C1-4 alkyl; R6 is C1-4 alkyl or halo; m is 0, 1 or 2; n is 0, 1, 2, 3, 4 or S; and p is 0, 1, 2, 3, 4, 5 or 6. These compounds are useful for the treatment of medical conditions caused by bradykinin such as inflammation, cardiovascular disease, pain, etc. This invention also provides a pharmaceutical composition comprising the above compound.

Synthesis of various analog derivatives of ORG13514 as 5-HT(1A) ligands

In connection with the development of new potential 5-HT(1A) ligands, multistep synthesis of N-substituted-3-aminomethyl-2,3-dihydro-1,4- dioxinol[2,3-b]pyridine derivatives as ORG13514 analogs are described. Their biological activity as 5-HT(1A) type lig

Antipsychotic benzoisothiazolyl piperazine derivatives

Compounds represented by the formula (I) and pharmacologically acceptable salts thereof: STR1 These compounds have little extrapyramidal effect and thus are effective as an anti-psychotic agent having few side effects.